Compare YieldMax Universe Fund of Option Income ETFs (YMAX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Universe Fund of Option Income ETFs vs Zimmer Biomet Holdings Inc — how do they compare? YieldMax Universe Fund of Option Income ETFs trades at $7.61 (market cap $364M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 46.6× YieldMax Universe Fund of Option Income ETFs's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Universe Fund of Option Income ETFs for 56 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| YMAX | ZBH | |
|---|---|---|
Market Cap | $364M | $16.95B |
Volume | 1,181,378 | 2,505,240 |
Sector | Income / Options Overlay | Health |
52-Week High | $12.70 | $103.98 |
52-Week Low | $7.27 | $79.58 |
Typical Hold Time | 56 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
YMAX trades at $7.48, down 0.66% with a bearish technical outlook. The ETF shows persistent NAV erosion despite high distributions, with the share price declining 22.7% year-to-date. Recent portfolio adjustments aim to address performance concerns, but structural costs and distribution sustainability remain key investor focus areas.
The fund faces significant headwinds from its fund-of-funds structure stacking costs, with a 1.33% base fee plus underlying ETF expenses. While offering 40%+ annualized yields, the distribution policy appears unsustainable given NAV declines. Investors face principal erosion risks despite high income payments.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
